Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) rose 8.8% during mid-day trading on Wednesday . The company traded as high as $47.25 and last traded at $46.50. Approximately 1,677,535 shares changed hands during trading, an increase of 144% from the average daily volume of 688,418 shares. The stock had previously closed at $42.75.

SUPN has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price objective for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $61.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $49.90.

The stock has a market cap of $2,380.00, a P/E ratio of 42.27 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. Supernus Pharmaceuticals’s quarterly revenue was up 41.5% compared to the same quarter last year. research analysts anticipate that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total value of $2,178,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Victor Vaughn sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the sale, the vice president now directly owns 24,344 shares of the company’s stock, valued at $1,023,421.76. The disclosure for this sale can be found here. Insiders sold 145,750 shares of company stock valued at $6,173,173 over the last three months. 6.70% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC increased its position in shares of Supernus Pharmaceuticals by 6.9% in the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after acquiring an additional 29,939 shares during the period. Royal Bank of Canada increased its position in shares of Supernus Pharmaceuticals by 790.8% in the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock valued at $11,699,000 after acquiring an additional 240,978 shares during the period. First Trust Advisors LP purchased a new position in shares of Supernus Pharmaceuticals in the third quarter valued at about $2,255,000. State Street Corp increased its position in shares of Supernus Pharmaceuticals by 3.1% in the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after acquiring an additional 42,165 shares during the period. Finally, Pictet Asset Management Ltd. increased its position in shares of Supernus Pharmaceuticals by 438.7% in the third quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after acquiring an additional 400,083 shares during the period. 98.22% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/01/17/supernus-pharmaceuticals-supn-stock-price-up-8-8.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.